Abstract
This pilot study was aimed at evaluation of ADRB2 and CHRM3 gene expression in COPD. Methods. We evaluated ADRB2 and CHRM3 gene expression in blood leukocytes from 29 patients with acute exacerbation of COPD (GOLD stage II to III, Group D) before and after 2-week combined therapy including antimicrobials, tiotropium bromide, formoterol and an inhaled steroid. ADRB2- and CHRM3-specific mRNA content was determined in leukocytes using real-time PCR. Results. Mean gene expression levels did not differ before and after treatment. However, we found a significant correlation between changes in ADRB2 and CHRM3 gene expression, change in FEV1 and post-treatment C-reactive protein level. Conclusion. The results confirm a possibility to affect adrenoceptors using beta agonists and inhaled steroids and to inhibit M-cholinoreceptor expression with M3-cholinolytics and inhaled steroids.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
